Experts in genome engineering: the genegineers

Cellectis bioresearch was incorporated as a subsidiary of Cellectis, and provides life science researchers with genome customization products and services.

These products and services, based on sequence-specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.

Since its inception in 1999, Cellectis has been a pioneer in the field of genome engineering. Our parent company has extensive experience on Meganuclease and TALEN™, engineering and expertise in DNA repair processes such as homologous recombination and non homologous end-joining.

Meganucleases and TALENs™ are highly specific DNA endonucleases that enable precise modifications of genomic DNA, with applications in the research, bioproduction, agrobiotechnology, and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of 83 patents granted and more than 300 patent applications pending. 

Cellectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS). The company has raised €130 million since inception, including €50 million in November 2011 from the FSI and Mr. Pierre Bastid.